Atea Pharmaceuticals appoints Arthur Kirsch to Board of Directors

Atea Pharmaceuticals, Inc.

Arthur Kirsch, age 73, elected as Class I director effective February 20, 2025.
Kirsch brings experience as Senior Advisor at Alvarez & Marsal Life Sciences Industry Group.
Annual cash retainer of $45,000 plus initial option to purchase 164,800 shares vesting over 36 months.
Kirsch currently serves on board of Liquidia Technologies (LQDA); previously on boards of Kadmon, Immunomedics, POZEN, Aralez.
Compensation follows Non-Employee Director Compensation Program disclosed in Q2 2024 Form 10-Q.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Arthur Kirsch

Class I director

AVIR · Atea Pharmaceuticals, Inc.

Effective: 2025-02-20
Filed: February 24, 2025, 6:59 PM ET

On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Arthur Kirsch was elected as Class I director at Atea Pharmaceuticals, Inc..

Action: elected
Role: Class I director

Exact text from the filing

On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.

View on SEC.gov

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-032826

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.